IRCT20150905023897N5已完成2 期
To evaluate the effectiveness of Silymarin (Livergol) on IL-6 levels and size of endometrioma lesions in women with ovarian endometriosis: a randomized, double-blind placebo-controlled trial
Vice chancellor for research Tarbiat Modares University0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15 years 至 49 years（—）
- 性别
- Female
入选标准
- •Iranian married women of reproductive age (15-49)
- •No chronic disease (diabetes, hypertension, liver and kidney disease, previous venous embolism ...) based on medical records
- •Women with a confirmed diagnosis of ovarian endometriosis via transvaginal ultrasonography performed by a single sonologist and CA125 level
- •People are willing to participate in the study
排除标准
- •participants suffering from the side effects of silymarin
- •Individuals unwilling to continue participating in the study
- •Failure to comply with treatment protocol
- •Taking specific medications such as anti-depressant, GnRH analogues, systemic glucocorticoids, or other milk thistle products and anti-inflammatory supplements with a specified wash-out period for each one
研究者
相似试验
尚未招募
2 期
Silymarin capsule in COVID-19COVID-19 disease.COVID-19U07.1IRCT20180103038199N10Mashhad University of Medical Sciences140
尚未招募
3 期
Evaluating the effectiveness of silymarin in preventing vancomycin nephrotoxicityVancomycin-induced nephrotoxicity in hospitalized patients.Drug- and heavy-metal-induced tubulo-interstitial and tubular conditionsIRCT20161010030246N6Shiraz University of Medical Sciences80
招募中
3 期
Silymarin in multiple SclerosisTherapeutic effect of silymarin.IRCT20171220037977N1Esfahan University of Medical Sciences60
已完成
3 期
The effect of silymarin on methadone poisoningIRCT20210216050377N1Shahre-kord University of Medical Sciences64
招募中
3 期
Evaluating the effectiveness of Silymarin on the prevention of gentamicin nephrotoxicityGentamicin-induced renal toxicity in hospitalized patients.Other bacterial diseasesA30-A49IRCT20161010030246N3Shiraz University of Medical Sciences60